Penn SICCA Follow-up Study
NCT05056012 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 220
Last updated 2026-03-02
Summary
This study will involve the collection of follow-up data for patients who previously participated in the Sjogren's International Clinical Collaborative Alliance (SICCA) study at the University of Pennsylvania. Clinical data and specimens will be collected from subjects with objective evidence of dry eye who were or were not diagnosed with Sjogren's syndrome at the time of their initial participation in the SICCA study. Specimens will be collected from participants which will include tears, saliva, whole blood, serum, DNA and possible labial minor salivary gland biopsies when indicated. All individuals will participate in a standard evaluation protocol including an oral, ocular and physical examination, objective tests for dry eyes and dry mouth and, whenever necessary, a labial minor salivary gland biopsy. The biopsy requirement is waived for those who have already had positive lip biopsies in the past.
Conditions
- Dry Eye
- Sjogren's Syndrome
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Vatinee Bunya, MD · Scheie Eye Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2027-01-31
- Primary Completion
- 2029-01-31
- Completion
- 2029-01-31
Countries
- United States
Study Locations
More Related Trials
-
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
NCT00377949 ·Status: COMPLETED
-
Prevalence and Factors of Sarcopenia and in Patients With Primary Sjogren's Syndrome
NCT05015114 ·Status: COMPLETED
-
The Possible Association Between Pseudoexfoliation Syndrome And Corneal Endothelial Cell Changes
NCT05156138 ·Status: UNKNOWN
-
Calcinosis in a Single-Center Scleroderma Population
NCT02062125 ·Status: COMPLETED
-
Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular Surface
NCT05302609 ·Status: TERMINATED ·Phase: PHASE2
-
Implementation of a Biological Sample Collection in Systemic Sclerosis Patients
NCT04986514 ·Status: WITHDRAWN
-
Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers
NCT01971957 ·Status: COMPLETED
-
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
NCT00946699 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Screening Strategies for Scleroderma PAH
NCT01959815 ·Status: COMPLETED
-
Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
NCT05380804 ·Status: COMPLETED
-
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
NCT05149768 ·Status: RECRUITING ·Phase: PHASE2
-
Primary Sjögren Syndrome
NCT01989819 ·Status: COMPLETED
-
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
NCT01881529 ·Status: COMPLETED
-
Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)
NCT00706082 ·Status: TERMINATED
-
Stem Cell Factor, a Potential Biological Marker of Skin Involvement in Systemic Sclerosis?
NCT05482594 ·Status: UNKNOWN
-
N-acetylcysteine for Primary Sjögren's Syndrome
NCT04793646 ·Status: COMPLETED ·Phase: NA
-
The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)
NCT01778569 ·Status: COMPLETED
-
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
NCT01553981 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
NCT00070590 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
NCT03509064 ·Status: RECRUITING
-
Study of Silicone-Associated Connective Tissue Diseases
NCT00001330 ·Status: COMPLETED
-
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
NCT00883129 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT03274076 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Systemic Sclerosis Clinical and Biomarker Study
NCT02531009 ·Status: WITHDRAWN